GH Research (GHRS)
Develops mebufotenin therapies and delivery systems for treatment-resistant depression.
$27.86
After hours−0.05 (−0.18%)
At close$27.91(−0.07%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 75.13% | 51.51M ADS | |
|---|---|---|---|
| 68 holders · as of Jun 30, 2026 | |||
| Other | 24.87% | 17.05M ADS | |
| remainder | |||
68.56M ADS as of Sep 2, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13F, as of Jun 30, 2026
68 holders · 51.51M shares · 19 new positions · 37 increased · 17 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| LYNX1 Capital Management LP | 13.26M | 19.35% | +2.50M | Aug 13, 2026 |
| BVF Inc/IL | 8.65M | 12.62% | 0 | Aug 14, 2026 |
| Ra Capital Management, L.P. | 7.64M | 11.14% | −39.9K | Aug 14, 2026 |
| FMR LLC | 5.98M | 8.72% | +841.0K | Aug 13, 2026 |
| RTW Investments, LP | 5.93M | 8.66% | 0 | Aug 14, 2026 |
| Deep Track Capital, LP | 3.33M | 4.86% | +3.33Mnew | Aug 14, 2026 |
| Avoro Capital Advisors LLC | 1.80M | 2.63% | 0 | Aug 14, 2026 |
| Foresite Capital Management Vi LLC | 940.5K | 1.37% | +625.0K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 17.40% | 10.76M | 13G | May 18, 2026 |
| RA Capital Management, L.P. | 12.40% | 7.68M | 13G | Aug 14, 2025 |
| RTW Investments, LP | 8.90% | 5.50M | 13G | May 15, 2025 |
| FMR LLC | 8.20% | 5.09M | 13G | Aug 6, 2025 |
| Biotechnology Value Fund L P | 7.40% | 4.60M | 13G | May 15, 2025 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.